Koninklijke Philips NV (PHG)
20.02
-0.31
(-1.52%)
USD |
NYSE |
Mar 28, 13:29
Koninklijke Philips Research and Development Expense (Quarterly): 483.53M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 483.53M |
September 30, 2023 | 484.51M |
June 30, 2023 | 510.32M |
March 31, 2023 | 567.09M |
December 31, 2022 | 512.28M |
September 30, 2022 | 616.51M |
June 30, 2022 | 517.67M |
March 31, 2022 | 555.45M |
December 31, 2021 | 543.26M |
September 30, 2021 | 515.25M |
June 30, 2021 | 566.44M |
March 31, 2021 | 510.93M |
December 31, 2020 | 476.92M |
September 30, 2020 | 557.80M |
June 30, 2020 | 477.97M |
March 31, 2020 | 539.63M |
December 31, 2019 | 499.40M |
September 30, 2019 | 508.15M |
June 30, 2019 | 497.67M |
March 31, 2019 | 498.68M |
December 31, 2018 | 554.50M |
September 30, 2018 | 482.55M |
June 30, 2018 | 507.46M |
March 31, 2018 | 531.94M |
December 31, 2017 | 542.87M |
Date | Value |
---|---|
September 30, 2017 | 530.21M |
June 30, 2017 | 463.21M |
March 31, 2017 | 551.81M |
December 31, 2016 | 484.39M |
September 30, 2016 | 477.70M |
June 30, 2016 | 465.47M |
March 31, 2016 | 518.49M |
December 31, 2015 | 188.19M |
September 30, 2015 | 523.44M |
June 30, 2015 | 533.75M |
March 31, 2015 | 491.94M |
December 31, 2014 | 583.24M |
September 30, 2014 | 492.99M |
June 30, 2014 | 548.62M |
March 31, 2014 | 542.53M |
December 31, 2013 | 476.46M |
September 30, 2013 | 595.15M |
June 30, 2013 | 556.42M |
March 31, 2013 | 572.94M |
December 31, 2012 | 502.01M |
September 30, 2012 | 558.83M |
June 30, 2012 | 564.98M |
March 31, 2012 | 590.00M |
December 31, 2011 | 598.18M |
September 30, 2011 | 549.80M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
476.92M
Minimum
Dec 2020
616.51M
Maximum
Sep 2022
521.97M
Average
511.61M
Median
Research and Development Expense (Quarterly) Benchmarks
Cardinal Health Inc | -- |
TC BioPharm (Holdings) PLC | -- |
uniQure NV | 42.62M |
ProQR Therapeutics NV | 8.328M |
Adaptimmune Therapeutics PLC | 33.21M |